Perrigo spares little about Opill’s launch, advertising and outlook in Q1 earnings briefing, but management also makes clear it’s a large firm and some other segments of its global consumer health products business are holding back overall results.

Direct seller reports Q1 sales up 1% to $1.3bn but net sales off 17.1% from year-ago period to $24.3m. Its distributor ranks jumped so far in 2024, particularly in China, where changes were made in the past year including new company leadership.

Blink NutriTears supplement containing lutein/zeaxanthin, curcumin and vitamin D3 coming in 2024 is example of a cross-segment sales benefit B+L sees in dry eye product category. Consumer eye care and vision health product sales are key drivers for 18% Q1 net sales growth to $1.1bn.

Returning for its 29th year, the Oscars of the OTC industry is now inviting entries from UK consumer health players across 12 categories.

The regulation “is clear, as is the Court’s order” rejecting CRN’s motion for preliminary injunction against imposition of the regulation, says US district Judge Andrew Carter in order denying the trade group’s request for clarification of New York regulation.

Exclusion from procurement processes, confiscation of revenues, and a fine of at least 4% of annual turnover are some of the penalties the European Parliament is considering for greenwashing as part of its position on the EU Green Claims Directive. 

“So lacking in substance that it ‘stands out’ from the dozens of [patent infringement] challenges I have encountered as a judge in the last five years,” says Colm Connolly, Delaware district chief judge. His ruling doesn’t end the firms’ litigation as related cases continue in federal courts in California and New York.

“No” answers in New York federal court on whether all but two of Prevagen claims were “materially misleading” could put a fork in the road of a long dispute between FTC and supplement product manufacturers and marketers.

FTC Division of Marketing Practices assistant director concerned direct selling self-regulation group’s guidance “will encourage deceptive conduct and facilitate deceptive earnings claims.” DSA president says the concerns might reflect the thinking of agency’s staff more than the intent of the agency’s regulations.